Venetoclax

Real-world outcomes of venetoclax + azacitidine versus intensive chemotherapy in newly diagnosed AML

Phase Ib study of venetoclax plus azacitidine in patients with R/R MDS

Key MDS updates from the 2021 ASH meeting

The future of fixed-duration therapy in CLL

Discussing FLT3-mutated AML: top ASH data, triplets, and exciting future strategies

The future of CLL treatment

2 year DFS data from the CAPTIVATE trial

GAIA/CLL13: Venetoclax-based time-limited combination therapies in CLL

HOVON 141/VISION: MRD guided time-limited treatment in CLL

GLOW: Assessing ibrutinib plus venetoclax in CLL

Treating Richter’s transformation with venetoclax, obinutuzumab and atezolizumab

ReVenG: Venetoclax and obinutuzumab in CLL

MAJIC: Venetoclax with acalabrutinib or obinutuzumab in CLL

Atezolizumab with venetoclax and obinutuzumab in patients with CLL

First-line ibrutinib and venetoclax in CLL

Phase Ib/II study of magrolimab in combination with azacitidine and venetoclax in patients with AML